产品说明书
Buloxibutid
 |
同义名 : | Compound 21;AT2 Agonist C21;M24;C21;AT2 receptor agonist C21 |
| CAS号 : | 477775-14-7 | |
| 货号 : | A775035 | |
| 分子式 : | C23H29N3O4S2 | |
| 纯度 : | 98% | |
| 分子量 : | 475.624 | |
| MDL号 : | MFCD26936332 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Room temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(220.76 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | AT2R Agonist C21 is an angiotensin II type 2 receptor agonist. Compound 21 (0.12 mg/kg/day for 4 weeks, p.o.) treatment improved fine motor skills after MCAO (middle cerebral artery occlusion) through modulation of the microglia/macrophage inflammatory properties. In addition, C21 increased M2 polarization and reduced the M1:M2 ratio in vitro. Thus, delayed administration of C21 downregulates post-stroke inflammation in female diabetic animals[3]. AT2R agonist C21 effectively prevents the development of PSCI in aged animals[4]. The administration of C21 (0.1-10 μM/15 min) increased the surface levels of TRKB (tropomyosin-related kinase B receptors) but was not sufficient to increase the levels of phosphorylated TRKB (pTRKB) in cultured cortical neurons from rat embryos. Consistent with increased TRKB surface expression, C21 (10 μM/15 min or 3 days) facilitated the effect of BDNF (0.1 ng/mL/15 min) on pTRKB in these cells[5]. In cultured human RPE cells, activation of AT2R with C21 significantly blocked Angiotensin II, LPS and hydrogen peroxide -induced NF-κB activation and inflammatory cytokine expression[6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.10mL 0.42mL 0.21mL |
10.51mL 2.10mL 1.05mL |
21.03mL 4.21mL 2.10mL |
| 参考文献 |
|---|